ID
24676
Description
Study ID: 101468/228 Clinical Study ID: 101468/228 Study Title:A two year Phase IIIb randomised, multicenter, double-blind, SINEMET controlled, parallel group, flexible dose study, to assess the effectiveness of controlled release ropinirole add-on therapy to L-dopa at increasing the time to onset of dyskinesia in Parkinson's disease subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363727 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Dyskinesias; Parkinson Disease; Parkinson's Disease Study part: Dyskinesias.
Keywords
Versions (2)
- 8/12/17 8/12/17 -
- 9/8/17 9/8/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
August 12, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Dyskinesias GSK study Dyskinesia in Parkinson's disease NCT00363727
Dyskinesias GSK study Dyskinesia in Parkinson's disease NCT00363727
Description
Dyskinesia
Description
Complete the Dyskinesia panel at each visit. Determine, using your own clinical judgement whether the subject has dyskinesia. Do not confuse morning dystonia for dyskinesia. If dyskinesia is Yes, make sure all information is transferred to the Early Withdrawal Visit and that the Study Conclusion page is completed correctly.
Data type
boolean
Description
If you have determined that the subject has dyskinesia, Check Yes for dyskinesia and complete the bottom part of the dyskinesia panel to explain how you reach your conclusion. That is, (1) you observed the subject in clinic with dyskinesia, or (2) the verbal history that the subject related to you at this visit clearly and unequivocally provided an account of dyskinesia even though it was not present during the visit. Where there is doubt as to whether the verbal description provided by the subject was not clear enough to be considered dyskinesia. then make a note to this effect in your source documents and check No on the dyskinesia panel. If at the next consecutive visit the subject provides you with a similar account, you may then note this subject as dyskinetic and check the third check box, History suspicious and noted at 2 consecutive visits.
Data type
integer
Description
Make sure the date of onset of dyskinesia is between the last visit date and this visit date.
Data type
date